Experimental drug targets rare fat Disorder's metabolic woes

NCT ID NCT05088460

Terminated Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a drug called REGN4461 (mibavademab) in 20 people with familial partial lipodystrophy, a rare condition causing abnormal fat distribution and metabolic problems. The study aimed to see if the drug could lower high triglycerides and improve blood sugar control. However, the trial was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: REGN4461 (mibavademab)
What this could lead to: If it works, this could point toward a treatment to control metabolic problems like high triglycerides and blood sugar in people with familial partial lipodystrophy.
What could go wrong: The trial was terminated early, so results are limited. It was a small phase 2 study with only 20 participants, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FAMILIAL PARTIAL LIPODYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

familial partial lipodystrophy metabolic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FAMILIAL PARTIAL LIPODYSTROPHY METABOLIC ABNORMALITIES

Contacts and locations

Locations

Complexo Hospitalario Universitario de Santiago-Hospital Médico-Cirúrxico de Conxo

Santiago de Compostela, Galicia, 15706, Spain
Ege University Faculty of Medicine

Izmir, Bornova, 35100, Turkey (Türkiye)
Excel Medical Clinical Trials - A Flourish Research Site

Boca Raton, Florida, 33434, United States
ICAN, Institute of Cardiometabolism and Nutrition

Paris, 75013, France
National Institute of Health

Bethesda, Maryland, 20892, United States
UT Southwestern Medical Center

Dallas, Texas, 75390, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.